Biosimilars are a prescription for better health.

Biosimilars could lead to over $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines.

Learn More

The Biosimilars Council - Dark Transparent Overlay
grx+biosims logo white

The GRx+Biosims 2020 virtual conference is now available on-demand.

Access special presentations from industry experts and key influencers at a great price.

Biosimilars: A needed alternative to costly care.

Utilization of innovative and very costly medicines is expected to grow exponentially in the coming years. With biosimilars, these advanced treatments are poised to become available at a lower cost to millions of patients in the United States. A positive regulatory environment can increase biosimilar adoption.


Browse our Resources

Hear more from experts on the potential of biosimilars and learn about Biosimilars Council efforts to increase biosimilar access for patients.


Want to keep up-to-date?

Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.

  • This field is for validation purposes and should be left unchanged.

FDA Biosimilars Approvals

Find an up-to-date list of FDA approved biosimilars and launches.

Featured Reports & Resources

These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.

2020 Generics & Biosimilars Savings Report

Recent Tweets

At the #GRxBiosims conference in November 2020, HHS Secretary @SecAzar spoke about the transformation #biosimilars could bring to patient care. Biosimilars have the potential to bring billions in savings to America’s patients.

Watch sessions on demand:

Load More...